Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other Non-Current Assets (2019 - 2025)

Allogene Therapeutics' Other Non-Current Assets history spans 7 years, with the latest figure at $3.5 million for Q3 2025.

  • For Q3 2025, Other Non-Current Assets fell 65.87% year-over-year to $3.5 million; the TTM value through Sep 2025 reached $3.5 million, down 65.87%, while the annual FY2024 figure was $2.3 million, 64.79% down from the prior year.
  • Other Non-Current Assets for Q3 2025 was $3.5 million at Allogene Therapeutics, down from $10.3 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $10.3 million in Q4 2021 and bottomed at $2.3 million in Q4 2024.
  • The 5-year median for Other Non-Current Assets is $9.4 million (2023), against an average of $8.3 million.
  • The largest annual shift saw Other Non-Current Assets soared 119.8% in 2021 before it plummeted 65.87% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $10.3 million in 2021, then fell by 7.07% to $9.6 million in 2022, then tumbled by 30.95% to $6.6 million in 2023, then plummeted by 64.79% to $2.3 million in 2024, then surged by 51.1% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Other Non-Current Assets are $3.5 million (Q3 2025), $10.3 million (Q2 2025), and $10.3 million (Q1 2025).